News Mixed outcomes for pharma in big week for FDA adcomms There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.
News UroGen’s urothelial cancer drug bags FDA approval The FDA has approved UroGen’s Jelmyto (mitomycin gel) as the first therapy to treat low-grade upper tract urothelial cancer (UTUC).
News UroGen appoints former Novartis cancer chief Barrett as CEO Novartis’ former oncology CEO Liz Barrett has left to join a little known biotech, UroGen, to help bring its potential urothelial cancer drug to market.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
